Please login to the form below

Not currently logged in
Email:
Password:

Bayer signs away Yasmin rights

Bayer Healthcare has signed a new agreement which gives US biotech company, Barr Laboratories, rights to sell the generic version of its oral contraceptive pill

Bayer Healthcare has signed a new agreement which gives US biotech company, Barr Laboratories, rights to sell the generic version of its oral contraceptive pill, Yasmin, in a bid to stave off the financial hit from impending patent expiry of the brand.

The US drug manufacturer is currently appealing a New Jersey court ruling that effectively invalidated its patent for the contraceptive drug. Bayer stands to receive a fixed percentage of the profits from Barr's sales of the generic version of the product. However, should Bayer be successful in its appeal against the New Jersey court decision regarding the Yasmin patent, the company will receive a larger share of the profits from Barr's sales of the generic version.

Barr will only have the right to sell the drug on the US market but has also been given a marketing licence for YAZ, a sister product to Yasmin, as they both come from the same family of drospirenone treatments. The licence for YAZ means that Barr will be allowed to supply and market the generic version of the product should Bayer's appeals against other companies regarding patent protection fail.

Dr Gunnar Riemann, member of the board of management at Bayer, said that he hopes the company will continue posting high-single-digit to low-double-digit percentage growth rates.

"The agreement allows us to participate in the US market for generic oral contraceptives in partnership with an established player," he said.

24th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics